Payment overview · 2025
General Payments
$2,453.32
57 reported records · 10 companies
Healthcare provider profile · identity verified
Taylor Barger, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · MONTOURSVILLE, PA · NPI 1053740696
Verified facts
What the public records show
CMS Open Payments records show Taylor Barger, PA-C received $2,453.32 in general payments during 2025 across 57 reported records.
Novo Nordisk Inc accounted for 73.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Xifaxan.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $1,790.43 | 73.0% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $288.66 | 11.8% | 22 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $94.54 | 3.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.14 | 3.0% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $52.72 | 2.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.22 | 2.1% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $46.37 | 1.9% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.40 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.55 | 0.8% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $14.29 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $1,590.00 | 2 |
| Food and Beverage | $863.32 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $1,626.89 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $288.66 | 22 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $239.67 | 17 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $187.45 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $94.54 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $52.72 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.22 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.22 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.32 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.32 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $46.37 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.63 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $12.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 69 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 98 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
98 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
140 | 23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 493 | 120 |
| Atorvastatin Calcium | Atorvastatin Calcium | 490 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 270 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 221 | 60 |
| Losartan Potassium | Losartan Potassium | 219 | 52 |
| Omeprazole | Omeprazole | 210 | 55 |
| Metformin Hcl | Metformin Hcl | 206 | 52 |
| Gabapentin | Gabapentin | 200 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 34 |
| Eliquis | Apixaban | 140 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 37 |
| Potassium Chloride | Potassium Chloride | 134 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 22 |
| Simvastatin | Simvastatin | 113 | 31 |
| Sertraline Hcl | Sertraline Hcl | 106 | 23 |
| Famotidine | Famotidine | 105 | 26 |
| Furosemide | Furosemide | 102 | 30 |
| Ozempic | Semaglutide | 98 | 15 |
| Carvedilol | Carvedilol | 86 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 26 |
| Allopurinol | Allopurinol | 77 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 24 |
| Jardiance | Empagliflozin | 77 | 18 |
| Lorazepam | Lorazepam | 75 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 19 |
| Montelukast Sodium | Montelukast Sodium | 69 | 18 |
| Mounjaro | Tirzepatide | 69 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 22 |
| Tramadol Hcl | Tramadol Hcl | 59 | suppressed |
| Atenolol | Atenolol | 58 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 15 |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 50 | 15 |
| Ketoconazole | Ketoconazole | 49 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | suppressed |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 11 |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | 11 |
| Meloxicam | Meloxicam | 30 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Xifaxan | Rifaximin | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 13 |
| Fluconazole | Fluconazole | 21 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Prednisone | Prednisone | 17 | 16 |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,453.32 · 57 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, CeQur Simplicity, IBSRELA, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, UBRELVY, VOQUEZNA, WATCHMAN FLX, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error